Chen PH, et al. Classifying ischemic stroke, from TOAST to CISS. CNS Neurosci Ther. 2012;18(6):452–6. https://doi.org/10.1111/j.1755-5949.2011.00292.x.

Article  PubMed  PubMed Central  Google Scholar 

Li X, et al. Association of type 2 diabetes mellitus and glycemic control with intracranial plaque characteristics in patients with acute ischemic stroke. J Magn Reson Imaging. 2021;54(2):655–66. https://doi.org/10.1002/jmri.27614.

Article  PubMed  Google Scholar 

Plitt A, McGuire DK, Giugliano RP. Atrial fibrillation, type 2 diabetes, and non-vitamin K antagonist oral anticoagulants: a review. JAMA Cardiol. 2017;2(4):442–8. https://doi.org/10.1001/jamacardio.2016.5224.

Article  PubMed  Google Scholar 

Koufakis T, et al. Sodium-glucose co-transporter 2 inhibitors versus metformin as the first-line treatment for type 2 diabetes: is it time for a revolution? Cardiovasc Drugs Ther. 2023;37(2):315–21. https://doi.org/10.1007/s10557-021-07249-0.

Article  CAS  PubMed  Google Scholar 

Dai W, et al. Empagliflozin demonstrates neuroprotective and cardioprotective effects by reducing ischemia/reperfusion damage in rat models of ischemic stroke and myocardial infarction. Sci Rep. 2025;15(1):8986. https://doi.org/10.1038/s41598-025-93483-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu G, et al. Pre-ischaemic empagliflozin treatment attenuates blood-brain barrier disruption via β-catenin mediated protection of cerebral endothelial cells. Cardiovasc Res. 2025;121(5):788–802. https://doi.org/10.1093/cvr/cvaf026.

Article  CAS  PubMed  Google Scholar 

Takashima M, et al. Low-dose sodium-glucose cotransporter 2 inhibitor ameliorates ischemic brain injury in mice through pericyte protection without glucose-lowering effects. Commun Biol. 2022;5(1):653. https://doi.org/10.1038/s42003-022-03605-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shim B, et al. Canagliflozin, an inhibitor of the NA(+)-coupled D-glucose cotransporter, sglt2, inhibits astrocyte swelling and brain swelling in cerebral ischemia. Cells. 2023. https://doi.org/10.3390/cells12182221.

Article  PubMed  PubMed Central  Google Scholar 

Amin EF, Rifaai RA, Abdel-latif RG. Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidative–inflammatory–apoptotic pathway. Fundam Clin Pharmacol. 2020;34(5):548–58. https://doi.org/10.1111/fcp.12548.

Article  CAS  PubMed  Google Scholar 

Sa-nguanmoo P, et al. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. Toxicol Appl Pharmacol. 2017;333:43–50. https://doi.org/10.1016/j.taap.2017.08.005.

Article  CAS  PubMed  Google Scholar 

Abdel-Latif RG, Rifaai RA, Amin EF. Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia/reperfusion injury through HIF-1α/VEGF signaling pathway. Arch Pharm Res. 2020;43(5):514–25. https://doi.org/10.1007/s12272-020-01237-y.

Article  CAS  PubMed  Google Scholar 

Vercalsteren E, et al. The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice. Cardiovasc Diabetol. 2024;23(1):88. https://doi.org/10.1186/s12933-024-02174-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Simanenkova A, et al. Microglia involvement into acute and chronic brain damage in diabetic rats: impact of GLP-1RA and SGLT-2i. Front Biosci Landmark. 2024;29(7):265. https://doi.org/10.31083/j.fbl2907265.

Article  CAS  Google Scholar 

Li CX, et al. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis. PLoS ONE. 2021;16(2):e0244689. https://doi.org/10.1371/journal.pone.0244689.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim JS, et al. Comparative effect of glucose-lowering drugs for type 2 diabetes mellitus on stroke prevention: a systematic review and network meta-analysis. Diabetes Metab J. 2024;48(2):312–20. https://doi.org/10.4093/dmj.2022.0421.

Article  PubMed  PubMed Central  Google Scholar 

Ng PY, et al. Atherothrombotic outcomes after sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: a territory-wide retrospective cohort study. J Am Heart Assoc. 2025;14(1):e037207. https://doi.org/10.1161/JAHA.124.037207.

Article  CAS  PubMed  Google Scholar 

Kim H, et al. Comparing ischemic cardiovascular effectiveness and safety between individual SGLT-2 inhibitors and DPP-4 inhibitors in patients with type 2 diabetes: a nationwide population-based cohort study. Front Pharmacol. 2024;15:1443175. https://doi.org/10.3389/fphar.2024.1443175.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee S, et al. Comparison of sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor on the risks of new-onset atrial fibrillation, stroke and mortality in diabetic patients: a propensity score-matched study in Hong Kong. Cardiovasc Drugs Ther. 2023;37(3):561–9. https://doi.org/10.1007/s10557-022-07319-x.

Article  CAS  PubMed  Google Scholar 

Shin H, et al. Comparative effectiveness of individual sodium-glucose cotransporter 2 inhibitors. JAMA Intern Med. 2025;185(3):302. https://doi.org/10.1001/jamainternmed.2024.7357.

Article  CAS  PubMed  Google Scholar 

Bantounou MA, et al. Meta-analysis of sotagliflozin, a dual sodium-glucose-cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes. ESC Heart Fail. 2025;12(2):968–79. https://doi.org/10.1002/ehf2.15036.

Article  PubMed  Google Scholar 

Pasqualotto E, et al. The effect of sodium-glucose transporter 2 inhibitors on stroke in patients with type 2 diabetes: a meta-analysis. J Stroke Cerebrovasc Dis. 2024. https://doi.org/10.1016/j.jstrokecerebrovasdis.2024.107730.

Article  PubMed  Google Scholar 

Chen TY, et al. Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: sodium-glucose cotransporter 2 inhibitors users versus non-users. A propensity score matching national cohort study. Diabetes Obes Metab. 2024;26(10):4501–9. https://doi.org/10.1111/dom.15804.

Article  CAS  PubMed  Google Scholar 

Fatima K, et al. The effect of sodium-glucose co-transporter 2 inhibitors on stroke and atrial fibrillation: a systematic review and meta-analysis. Curr Probl Cardiol. 2023;48(4):101582. https://doi.org/10.1016/j.cpcardiol.2022.101582.

Article  PubMed  Google Scholar 

Barkas F, et al. Sodium-glucose cotransporter-2 inhibitors and protection against stroke in patients with type 2 diabetes and impaired renal function: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2021;30(5):105708. https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.105708.

Article  PubMed  Google Scholar 

Zhou Z, et al. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis. Stroke. 2021;52(5):1545–56. https://doi.org/10.1161/STROKEAHA.120.031623.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mori Y, et al. Sodium-glucose cotransporter 2 inhibitors and cardiovascular events among patients with type 2 diabetes and low-to-normal body mass index: a nationwide cohort study. Cardiovasc Diabetol. 2024;23(1):372. https://doi.org/10.1186/s12933-024-02478-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zuo Q, et al. Canagliflozin attenuates hepatic steatosis and atherosclerosis progression in western diet-fed ApoE-knockout mice. Drug Des Devel Ther. 2022;16:4161–77. https://doi.org/10.2147/DDDT.S388823.

Article  PubMed  PubMed Central  Google Scholar 

Nakatsu Y, et al. The SGLT2 inhibitor luseogliflozin rapidly normalizes aortic mRNA levels of inflammation-related but not lipid-metabolism-related genes and suppresses atherosclerosis in diabetic ApoE KO mice. Int J Mol Sci. 2017.